


Platelet-Rich Plasma

James M. Saucedo, MD, MBA, Mark A. Yaffe, MD, John C. Berschback, MD,
Wellington K. Hsu, MD, David M. Kalainov, MD



SEVERAL INJECTABLE SUBSTANCES have been studied for the treatment of tendinitis of the hand, wrist, and elbow, including corticosteroids, botulinum toxin, autologous blood, and platelet-rich plasma (PRP).¹⁻⁸ Whereas empiric data suggest a beneficial effect of many treatments for tendinitis, defined roles for these various injections remain unclear. For several years, orthopedic surgeons have used PRP to treat conditions such as tendinitis about the knee, hip, and shoulder⁹⁻¹¹; however, data are inconclusive as to its precise mechanism of action as well as whether it demonstrates lasting benefit. We review the composition and preparation of PRP and list several of the available kits for its preparation.

BACKGROUND

Blood consists of cellular elements (erythrocytes, leukocytes, and platelets) and plasma (the liquid component of blood that is predominantly water but also contains clotting factors, proteins, glucose, minerals, carbon dioxide, and oxygen). Platelets are nonnucleated blood cells that originate as megakaryocyte fragments and circulate throughout the body to provide hemostasis by means of clot formation. So-called "platelet-rich plasma" represents the patient's own plasma that has been mechanically treated to increase the concentration of platelets compared to whole blood. The supra-physiological concentration of platelets will provide a locally increased concentration of growth factors and cytokines that are contained within the platelets themselves.⁹⁻¹¹

A local injection of PRP is, therefore, believed to work by releasing growth factors and cytokines that

recruit reparative cells and enhance the healing process at the injection site.^{2,3,8-10} There is *in vitro* evidence to support growth factor stimulation of tendon healing.¹² However, the exact growth factors and cytokines that are liberated, the precise mechanisms of action, the time courses of release and clearance, and the effects on both normal and abnormal tissues *in vivo* remain unclear.

During the past decade, PRP has been used with increasing frequency in the musculoskeletal system for the augmentation of bone grafts, treatment of knee osteoarthritis, supplementation of rotator cuff repairs, reconstructions of the anterior cruciate ligament, and management of patellar tendinopathy, plantar fasciitis, Achilles tendinosis, and refractory elbow epicondylitis.^{2,3,8,9} Many of the studies that have sought to support PRP injection are observational in nature and, therefore, have not provided conclusive evidence in favor of its routine use. However, well-designed outcome studies are emerging that show a potentially promising role for PRP in the management of chronic lateral epicondylitis.^{3,5,8}

PREPARATION AND CLASSIFICATION

At least 16 commercial PRP preparation systems are currently available (Table 1).¹³ A sample of peripheral venous blood is drawn and immediately spun in a centrifuge to separate the erythrocytes from the platelets and leukocytes. The increased density of the erythrocytes causes them to sink to the bottom of the centrifuge tube more rapidly than do the platelets and leukocytes. Further concentration then isolates PRP from platelet-poor plasma (Fig. 1).⁹ Commercially available PRP kits concentrate platelets in the final injectate up to 9 times the normal concentration found in whole blood. The resultant volume of PRP and the final platelet and leukocyte concentrations differ among preparation systems.⁹

Dohan Ehrenfest et al¹⁴ categorized PRP based on leukocyte and fibrin content. Mishra et al¹¹ classified PRP according to the platelet concentration, the presence of leukocytes, and the inclusion of an activator (Table 2).¹⁵ Platelets will increase anabolic signal-

From the Department of Orthopedic Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL.

Received for publication August 19, 2011; accepted in revised form December 12, 2011.

No benefits in any form have been received or will be received related directly or indirectly to the subject of this article.

Corresponding author: David M. Kalainov, MD, Department of Orthopedic Surgery, Northwestern University Feinberg School of Medicine, 676 N. St. Clair, Suite 1350, Chicago, IL 60611; e-mail: dkalainov@comcast.net.

0363-5023/12/37A03-0035\$36.00/0
doi:10.1016/j.jhsa.2011.12.026

ing, whereas leukocytes might release higher concentrations of catabolic signaling molecules.¹⁶ Exogenous platelet activators include calcium chloride and thrombin; both substances induce fibrin and create a putty-like or gel-like clot.⁹ The addition of an activator to PRP can diminish efficacy by decreasing the long-term availability of growth factors.¹⁷ Delivery of PRP without an activator is feasible because platelets are triggered to release growth factors and cytokines by exposure to tendon-derived collagen.^{2,3,9,17}

SAFETY

Given the autologous nature of PRP, safety concerns are minimal at this time. There have been reports of localized reactions to exogenous proteins such as fibrin. Nevertheless, the reported complications in most clinical series have been limited to transient pain and inflammation at the injection site.^{9,10,18} One laboratory study found that PRP has an antimicrobial effect against *Staphylococcus aureus* and *Escherichia coli*, potentially diminishing the risk for infection with these organisms.¹⁹ Platelet-rich plasma is

still considered investigational by many insurance carriers; consequently, there is an uncertain effect on the cost of treatment.

Platelet-rich plasma represents a supraphysiological concentration of platelets that is thought to work by delivering a locally increased concentration of growth factors and cytokines to damaged tissue, potentially stimulating soft tissue healing. Understanding the differences in PRP preparations is essential when interpreting clinical studies and considering concentrated platelets as a therapeutic option. Large prospective and randomized studies are necessary to investigate the efficacy of different preparations of PRP, controlling for hematologic differences between

patients (eg, platelet and leukocyte counts) and postinjection rehabilitation protocols.

REFERENCES

1. Faro F, Wolf JM. Lateral epicondylitis: review and current concepts. *J Hand Surg* 2007;32A:1271-1279.

TABLE 1. Representative Platelet-Rich Plasma Therapy Preparation Systems

System	Volume of Blood (mL)	Final PRP Volume (mL)	Final Platelet Concentration (Compared With Whole Blood)	Available Activator	Leukocyte Concentration ($\times 10^3/\mu\text{L}$) (Compared With Whole Blood)	Fibrinogen (mg/dL)
Autologous conditioned plasma (Arthrex, Naples, FL)	9	3-5	2-3 \times	None	N/A	N/A
Cascade (Musculoskeletal Tissue Foundation, Edison, NJ)	9 or 18	2 or 4	1.6 \times †	Calcium	1.1 \pm 0.2† (6-fold)	283.8 \pm 34.2†
GPS III (Biomet, Warsaw, IN)	27 or 54	3 or 6	2.1-9.3 \times ‡	Calcium chloride/ thrombin	34.4 \pm 13.6† (5-fold)	286.0 \pm 42.7†
SmartPReP (Harvest Technologies, Plymouth, MA)	20 or 60	3 or 7	4.4-7.6 \times	Thrombin	N/A	N/A
Magellan (Arteriocyte Inc, Cleveland, OH)†	30, 45, or 60†	Variable§	2.8-14 \times §	N/A§	11.0 \pm 8.2§ (2-fold)	277.4 \pm 30.5§

N/A, not available.

*Data obtained from Hall et al,⁹ except as otherwise noted.

†Data obtained from Castillo et al.¹³

‡Data obtained from manufacturer (<http://www.biomet.com/biologics/information/pdf/BBI0003.0.pdf>) and Castillo et al.¹³

§Data obtained from manufacturer (http://arteriocyte.com/amsi/professionals/Product_Magellan_Overview.asp) and Castillo et al.¹³




FIGURE 1: Extraction of platelet-rich plasma after withdrawing and discarding the platelet-poor plasma layer (GPS III, Biomet, Warsaw, IN).

TABLE 2. Mishra's Platelet-Rich Plasma Classification System^{11,15}

Type	Leukocyte Concentration	Activated
1 (A or B)	Increased over patient's baseline	No
2 (A or B)	Increased over patient's baseline	Yes
3 (A or B)	Few or no leukocytes	No
4 (A or B)	Few or no leukocytes	Yes

A, platelet concentration $\geq 5 \times$ patient's baseline; B, platelet concentration $\leq 5 \times$ patient's baseline.

- Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. *Am J Sports Med* 2006;34:1774-1778.
- Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. *Am J Sports Med* 2010;38:255-262.
- Szabo RM. Steroid injection for lateral epicondylitis. *J Hand Surg* 2009;34A:326-330.
- Creaney L, Wallace A, Curtis M, Connell D. Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, single-blind, randomized trial of autologous blood injections versus platelet-rich plasma injections. *Br J Sports Med* 2011;45:966-971.
- Thanasas C, Papadimitriou G, Charalambidis C, Paraskevopoulos I, Papanikolaou A. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial. *Am J Sports Med* 2011;39:2130-2134.
- Wolf JM, Ozer K, Scott F, Gordon MJ, Williams AE. Comparison of autologous blood, corticosteroid, and saline injection in the treatment of lateral epicondylitis: a prospective, randomized, controlled multicenter study. *J Hand Surg* 2011;36A:1269-1272.
- Gosens T, Peerbooms JC, van Laar W, den Ouden BL. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. *Am J Sports Med* 2011;39:1200-1208.
- Hall MP, Band PA, Meislin RJ, Jazrawi LM, Cardone DA. Platelet-rich plasma: current concepts and application in sports medicine. *J Am Acad Orthop Surg* 2009;17:602-608.
- Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. *Curr Rev Musculoskelet Med* 2008;1:165-174.
- Mishra A, Harmon K, Woodall J, Vieira A. Sports medicine applications of platelet rich plasma. *Curr Pharm Biotechnol* 2011 July 8. Epub ahead of print.
- Visser LC, Arnoczky SP, Caballero O, Egerbacher M. Platelet-rich fibrin constructs elute higher concentrations of transforming growth factor-beta 1 and increase tendon cell proliferation over time when compared to blood clots: a comparative *in vitro* analysis. *Vet Surg* 2010;39:811-817.
- Castillo TN, Pouliot MA, Kim HJ, Drago J. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. *Am J Sports Med* 2010;39:266-271.
- Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leukocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol* 2009;27:158-167.
- Daugherty K, Porucznik MA. Platelet-rich plasma: what's behind the hype? *AAOS Now* 2011;5. Available at: <http://www.aaos.org/news/aaosnow/jun11/clinical5.asp>. Accessed January 25, 2012.
- Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. *Am J Sports Med* 2011;39:2135-2140.
- Harrison S, Vavken P, Keyv S, Jacobson M, Zurawski D, Murray MM. Platelet activation by collagen provides sustained release of anabolic cytokines. *Am J Sports Med* 2011;39:729-734.
- Mei-Dan O, Mann G, Maffulli N. Platelet-rich plasma: any substance into it? *Br J Sports Med* 2010;44:618-619.
- Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Krol W, Wielkoszynski T. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: an *in vitro* study. *J Bone Joint Surg* 2007;89B:417-420.